[{"indications": "Indications\u00a0congestive heart failure where cardiac output reduced and filling\r\npressures increased", "name": "ENOXIMONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.1 Positive inotropic drugs", "2.1.2 Phosphodiesterase type-3 inhibitors", "ENOXIMONE"], "cautions": "Cautions\u00a0heart failure associated with hypertrophic cardiomyopathy, stenotic or obstructive\r\nvalvular disease or other outlet obstruction; monitor blood pressure, heart rate, ECG, central venous pressure, fluid and electrolyte status, renal function, platelet count, hepatic enzymes; avoid extravasation; interactions: Appendix 1 (phosphodiesterase\r\ntype-3 inhibitors)", "side-effects": "Side-effects\u00a0ectopic beats; less frequently ventricular tachycardia\r\nor supraventricular arrhythmias (more likely in patients with pre-existing\r\narrhythmias); hypotension; also headache, insomnia, nausea and vomiting,\r\ndiarrhoea; occasionally, chills, oliguria, fever, urinary retention;\r\nupper and lower limb pain", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2319.htm", "doses": ["By slow intravenous injection (rate not\r\nexceeding 12.5\u00a0mg/minute), diluted before use, initially 0.5\u20131\u00a0mg/kg,\r\nthen 500\u00a0micrograms/kg every 30\u00a0minutes until satisfactory response\r\nor total of 3\u00a0mg/kg given; maintenance, initial dose of up to 3\u00a0mg/kg\r\nmay be repeated every 3\u20136\u00a0hours as required", "By intravenous infusion, initially\r\n90\u00a0micrograms/kg/minute over 10\u201330\u00a0minutes, followed by continuous\r\nor intermittent infusion of 5\u201320\u00a0micrograms/kg/minute", "Total dose over 24\u00a0hours should not usually exceed 24\u00a0mg/kg"], "pregnancy": "Pregnancy\u00a0manufacturer advises use only if potential benefit\r\noutweighs risk"}]